Form 4: Summer Road LLC Acquires 930,851 Shares of Ocular Therapeutix in Private Placement

Summer Road LLC, a family office, purchased 930,851 shares of Ocular Therapeutix (OCUL) at $7.52 per share through a private placement.

Summary

• Summer Road LLC, a family office, acquired 930,851 shares of Ocular Therapeutix (OCUL) common stock at $7.52 per share on February 26, 2024, through a private placement.
• The purchase was made pursuant to a Securities Purchase Agreement dated February 21, 2024.
• Summer Road LLC also entered into a Registration Rights Agreement, requiring Ocular Therapeutix to register the shares for resale within 30 days of the closing.
• Summer Road LLC exercises voting and dispositive power over these shares through investment management agreements with its Family Clients.
• The shares are owned of record by Cap 1 LLC, a Family Client of Summer Road LLC, which is over 90% owned by Crystal Fiduciary Company, LLC, as Trustee of the AR Irrevocable Trust.
• Following the transaction, Summer Road LLC beneficially owns 8,591,401 shares of Ocular Therapeutix common stock through its Family Clients.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard transaction (private placement) with no explicit positive or negative implications. The increase in ownership by Summer Road LLC could be seen as a positive signal, but the potential for dilution and future resale temper the enthusiasm.

Positives

• Summer Road LLC's increased investment could signal confidence in Ocular Therapeutix's future prospects.
• The Registration Rights Agreement provides liquidity for Summer Road LLC's investment.

Risks

• The private placement could dilute existing shareholders if the newly issued shares are a significant portion of the outstanding shares.
• The subsequent resale of the acquired shares could create downward pressure on the stock price.

Future Outlook

The Issuer agreed to register for resale the Acquired Shares no later than 30 days following the closing of the Private Placement.

Industry Context

Private placements are a common method for companies, especially in the biotech sector, to raise capital. The involvement of a family office like Summer Road LLC suggests a long-term investment perspective.

Comparison to Industry Standards

• Comparable transactions include other private placements in the biotech industry, where institutional investors or family offices provide capital in exchange for equity.
• The terms of the Registration Rights Agreement are standard in private placements, ensuring liquidity for the investor.

Stakeholder Impact

• Shareholders may experience dilution if the private placement significantly increases the number of outstanding shares.
• The market price of Ocular Therapeutix stock could be affected by the resale of the acquired shares.

Next Steps

• Ocular Therapeutix will need to register the acquired shares for resale within 30 days of the closing date.
• Summer Road LLC may choose to sell some or all of its shares after registration.

Key Dates